References
- Qiu Y, Zhang G. Research and development aspects of oral controlled-release dosage forms. In: Wise DL, ed. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, Inc.; 2000:465–503
- Ratnaparkhi MP, Gupta JP. Sustained release oral drug delivery system: an overview. Int J Pham Res Rev 2013;2:11–21
- Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm 2004;30:429–48
- Douroumis D. Orally disintegrating dosage forms and taste-masking technologies. Drug Dev Ind Pharm 2011;8:665–75
- Guhmann M, Preis M, Gerber F, et al. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations. Drug Dev Ind Pharm. 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.884122
- Fung Tan Y, Khiang Peh K. Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer’s disease patients. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.884130
- Zhang L, Liu G, Dan H, et al. Novel taste-masked orally disintegrating tablets for a highly soluble drug with an extremely bitter taste: design rationale and evaluation. Drug Dev Ind Pharm 2013;39:1364–71
- Cantor SL, Khan MA, Gupta A. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride. Drug Dev Ind Pharm 2014:1–9 . [Epub ahead of print]. doi:10.3109/03639045.2014.935392
- Ge Z, Yang M, Wang Y, et al. Preparation and evaluation of orally disintegrating tablets of taste masked phencynonate HCl using ion-exchange resin. Drug Dev Ind Pharm 2014:1–10 . [Epub ahead of print]. doi: 10.3109/03639045.2014.914529
- Chivate A, Sargar V, Nalawade P, Tawde V. Formulation and development of oral dry suspension using taste masked Ornidazole particles prepared using Kollicoat(®) Smartseal 30 D. Drug Dev Ind Pharm 2013;39:1091–7
- Tan Q, Zhang L, Liu G, et al. Novel taste-masked orally disintegrating tablets for a highly soluble drug with an extremely bitter taste: design rationale and evaluation. Drug Dev Ind Pharm 2013;39:1397–71
- Tejashri G, Amrita B, Darshana J. Cyclodextrin based nanosponges for pharmaceutical use: a review. Acta Pharm 2013;63:335–58
- Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 2012;8:2091–9
- Liberman HA, Lachman L. Pharmaceutical dosage forms: dispersed systems. Volume I&II. 3rd Indian ed. Revised and expanded. New York: Marcel Dekker Inc.; 1994:479
- Jain DK, Darwhekar GN, Choudhary N. Formulation and evaluation of reconstitutable oral suspension of ambroxol HCl and azithromycin. Int J Pharm Tech Res 2011;2:741–6
- Sompur CK, Doijad RC, Patil SM, Maske AP. An approach for development of oral sustained release suspension. Int J Pharm Biol Sci 2011;2:320–9
- Dey NS, Majumdar S, Rao MEB. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008;7:1067–75
- Banday M, Sameer AS, Farhat S, Aziz R. Gabapentin: a pharmacotherapeutic panacea. Int J Pharm Pharm Sci 2013;5:84–94
- Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002;61:729–37
- Swaminathan S, Vavia P, Trotta F, et al. Formulation of betacyclodextrin based nanosponges of itraconazole. J Incl Phenom Macrocycl Chem 2007;57:89–94
- Higuchi T, Connors K. Phase solubility techniques. In: Reilly CN, ed. Advances in analytical chemistry and instrumentation. New York: Wiley Interscience; 1965:117–212
- Rao M, Bajaj A, Amol A. Investigation of nonporous colloidal carrier for solubility enhancement of cefpodoxime proxetil. J Pharm Res 2012;5:2496–9
- Margareth RC, Lobenberg R, Almukainze M. Simulated biological fluids with possible application in dissolution testing. Dissolut Technol 2011;18:15–28
- Anand V, Kharb V, Kataria M, et al. Taste assessment trials for sensory analysis of oral pharmaceutical products. Pak J Pharm Sci 2008;21:438–50
- Huda IG, Toshniwal SS. Chewable dispersible tablet of taste masked pregabalin. Int J Pharm Pharm Sci 2013;5:568–74
- Swaminathan S, Pastero L, Vavia P, et al. Cyclodextrin-based nanosponges encapsulating Camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 2010;74:193–201
- Asnani A, Parashar V. Development and in-vitro evaluation of controlled release multiparticulates of theophylline. Scholars Research Library. Pharm Lett 2013;5:284–91
- Indian Pharmacopoeia, Ministry of Health and Family Welfare. 7th ed. Vol. I. Ghaziabad: The Indian Pharmacopoeial Commission; 2014 253–6
- Akre HS, Mundhada DR, Bhaskaran S, et al. Dry suspension formulation of taste masked antibiotic drug for pediatric use. J Appl Pharm Sci 2012;2:166–71
- Sinko PJ. Martin’s physical pharmacy and pharmaceutical sciences. 5th Indian ed. Philadelphia: Lippincott Williams and Wilkins; 2006:533–60
- Suthar AM, Patel MM. Formulation and evaluation of taste masked suspension of Metronidazole. Int J Appl Pharma 2011;3:16–19
- Devrim B, Bozkir A, Canefe K. Formulation and evaluation of reconstitutable suspensions containing ibuprofen-loaded Eudragit microspheres. Acta Pol Pharma Drug Res 2011;68:593–9
- Narurkar M, Dalal P. In vitro & in vivo evaluation of sustained release suspension of Ibuprofen. Int J Pharm 1991;73:157–62
- Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem 2003;39:1033–46
- Pandey S, Kumar S, Prajapati SK, Stheesh Madhav NV. An overview on taste physiology and masking of bitter drugs. Int J Pharm BioSci 2010;1:1–11
- Rao M, Bajaj A, Khole I, et al. In vitro and in vivo evaluation of β-cyclodextrin-based nanosponges of Telmisartan. J Incl Phenom Macrocycl Chem 2013;77:135–45
- Raja C, Kiran Kumar G, Anusha K. Fabrication of Ciprofloxacin loaded nanosponges for sustained release. Int J Resin Pharm Nanosci 2013;2:1–9
- Lembo D, Swaminathan S, Donalisio M, et al. Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent’s antiviral efficacy. Int J Pharm 2013;443:262–72
- Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterization, stability, cytotoxicity and permeation study. AAPS PharmSciTech 2011;12:279–86
- Saenger W. Cyclodextrin inclusion compounds in research and industry. Angew Chem Int Ed Engl 1980;19:344–62
- Li N, Zhang YH, Wu YN, et al. Inclusion complex of trimethoprim with β-cyclodextrin. J Pharm Biomed Anal 2005;39:824–9
- Katikaneni PR, Upadrashta SM, Neau SH, Mitra AK. Ethylcellulose matrix controlled release tablets of a water-soluble drug. Int J Pharm 1995;123:119–25
- Plaizier J, Dauwe D, Brioen P. Possibility of the use of Eudragit RS as a sustained release matrix agent for the incorporation of watersoluble active compounds at high percentages. STP Pharma Sci 1997;7:491–7
- Kar RK, Mohapatra S, Barik B. Design and characterization of controlled release matrix tablets of zidovudine. Asian J Pharm Clin Res 2009;2:54–61
- Dey S, Pramanik S, Malgope A. Formulation and optimization of sustained release stavudin using response surface methodology. ISRN Pharm 2011;2011:1–7
- Raff AM, Arambulo AS, Perkins AJ, Geardroff DL. Compressed tablets: internal flow of granulation during compression. J Am Pharm Assoc Sci 1955;44:290–6